Refine
Has Fulltext
- yes (153)
Is part of the Bibliography
- yes (153)
Year of publication
Document Type
- Journal article (151)
- Doctoral Thesis (1)
- Other (1)
Language
- English (153) (remove)
Keywords
- children (11)
- inflammation (9)
- preterm infants (8)
- bronchopulmonary dysplasia (5)
- infection (5)
- influenza (5)
- IL-10 (4)
- Medizin (4)
- Ureaplasma parvum (4)
- autoimmunity (4)
- disease (4)
- immunotherapy (4)
- juvenile idiopathic arthritis (4)
- macrophages (4)
- monocytes (4)
- pediatric (4)
- treatment (4)
- vaccination (4)
- CRMO (3)
- HBMEC (3)
- NK cells (3)
- T cells (3)
- Th17 (3)
- Ureaplasma urealyticum (3)
- burden (3)
- cells (3)
- cytokines (3)
- immunization (3)
- physical activity (3)
- preterm birth (3)
- sepsis (3)
- surfactants (3)
- therapy (3)
- B cell (2)
- B cells (2)
- CNO (2)
- COVID-19 (2)
- Children (2)
- Cystic fibrosis (2)
- DIRA (2)
- Exercise capacity (2)
- Exercise testing (2)
- Germany (2)
- PAPA (2)
- Physical activity (2)
- Pädiatrie (2)
- Rheumatologie (2)
- SARS-CoV-2 (2)
- T cell receptor excision circles (2)
- TLR4 (2)
- TNF-α (2)
- Tregs (2)
- Wilms' tumor (2)
- animal model (2)
- blood–brain barrier (2)
- bone (2)
- cancer (2)
- case report (2)
- chronic non-bacterial osteomyelitis (2)
- chronic nonbacterial osteomyelitis (2)
- chronic recurrent multifocal osteomyelitis (2)
- cord blood (2)
- cystic fibrosis (2)
- deficiency (2)
- efficacy (2)
- endothelial cells (2)
- epithelial cells (2)
- expression (2)
- flow cytometry (2)
- gene (2)
- glucocorticoids (2)
- hospitalizations (2)
- hypophosphatasia (2)
- hypoxia (2)
- immunoblotting (2)
- in vitro (2)
- innate immunity (2)
- leukemia (2)
- medicine (2)
- meningitis (2)
- messenger RNA (2)
- neonate (2)
- neonates (2)
- nervous system (2)
- neuroinflammation (2)
- pediatric adrenocortical cancer (2)
- pediatric adrenocortical tumor (2)
- pediatrics (2)
- preterm (2)
- preterm infant (2)
- regulatory T cells (2)
- sustained inflammation (2)
- transplantation (2)
- treatment guidelines (2)
- tumor (2)
- tumor microenvironment (2)
- ACP5 (1)
- AD-AID (1)
- AICDA (1)
- AID-ΔE4a (1)
- ALPL (1)
- ARDS (1)
- Abatacept (1)
- Accelerometry (1)
- Age (1)
- Allogeneic stem cell transplantation (1)
- Anti-TNF-alpha agents (1)
- Antibody (1)
- Apoptosis (1)
- Aspergillus (1)
- Aspergillus fumigatus (1)
- Autoinflammation (1)
- B cell maturation (1)
- B cell receptor (1)
- B-cell (1)
- B4GALT7 gene (1)
- BPD (1)
- Bevacizumab (1)
- Big picture (1)
- Blood stream infection (1)
- Body composition (1)
- Bone health (1)
- Bronchopulmonary dysplasia (1)
- C-reactive protein (1)
- C5a (1)
- C5aR1 (1)
- CAR-T cells (1)
- CCN2 (1)
- CD105 (1)
- CD3/19 depletion (1)
- CD34 selection (1)
- CD62L (1)
- CD8 (1)
- CDR3 sequences (1)
- CMV (1)
- CNS cancer (1)
- CNS integrity (1)
- CTGF (1)
- CVID (1)
- CXCL5 (1)
- CXCL8 (1)
- CXCR2 (1)
- Cardiovascular disease (1)
- Caspase (1)
- Central venous access (1)
- Childhood cancer survivors (1)
- Chimeric Antigen Receptor T cells (1)
- Chorioamnionitis (1)
- Cigarette smoking (1)
- Coverage (1)
- Cushing (1)
- Cytokine GM-CSF (1)
- DC vaccination (1)
- DNA methylation (1)
- DNA-binding proteins (1)
- DWI (1)
- Deutschland (1)
- Disease severity (1)
- Diseases (1)
- Dixon (1)
- E. coli (1)
- ECORN-CF Projekt (1)
- ESPED (1)
- EU-RHAB registry (1)
- England (1)
- Epidemiology (1)
- Epidural Analgesia (1)
- Erratum (1)
- Escherichia coli (1)
- European experience (1)
- Exacerbation (1)
- Exercise intervention (1)
- Extraocular eye muscles (1)
- FADS (1)
- Foxp3 (1)
- GLDN variant (1)
- Gamma (1)
- Gastroenteritis (1)
- Glut1DS (1)
- Graft-versus-host disease (1)
- Grippe (1)
- H441 (1)
- HLA-G gene (1)
- HPP (1)
- HRQOL (1)
- Healthcare Cost (1)
- Healthcare Economics (1)
- Hemagglutination inhibition (1)
- Hickman catheter (1)
- Hospitalisation (1)
- Hospitalization (1)
- ICD-10 (1)
- IL-1 beta (1)
- IL-1 blockade (1)
- IL-10 expression (1)
- IL-12B (1)
- IL-12p40 (1)
- IL-17A-inhibition (1)
- IL12B (1)
- IMR-90 (1)
- IgD (1)
- IgG (1)
- IgM (1)
- Immunogenicity (1)
- Immunosenescence (1)
- Immunotherapy (1)
- Impfplan (1)
- Impfung (1)
- Incidence (1)
- Incontinentia pigmenti (1)
- Infectious disease (1)
- Influenza (1)
- Influenza vaccination (1)
- JIA (1)
- Jugend (1)
- Juvenile idiopathic arthritis (1)
- Keuchhusten (1)
- Kindergarten (1)
- LCCS11 (1)
- LND (1)
- LNE (1)
- Labour Analgesia (1)
- Labour Pain (1)
- Late-effects (1)
- Longitudinal analysis (1)
- Lung disease, (1)
- Lymphocytes (1)
- M1/M2 macrophages (1)
- MDSC (1)
- MHC I (1)
- MHC II (1)
- MRI spectroscopy (1)
- MTL30 (1)
- Majeed (1)
- Majeed-Syndrome (1)
- Masern (1)
- Mechanisms (1)
- Medicine (1)
- Meningitis (1)
- Metastases (1)
- Minor histocompatibility antigen mismatch transplantation (1)
- Mucopolysaccharidosis IIIa (1)
- Mumps (1)
- Muscle function (1)
- Muscle power (1)
- NADPH oxidase (1)
- Naive T cells (1)
- Necrotizing enterocolitis (1)
- Neuroinflammation (1)
- OPT (1)
- Oxygen uptake (1)
- P67(PHOX) (1)
- PAPA syndrome (1)
- PET/CT (1)
- PLAG1 rearrangement (1)
- POEM (1)
- PU.1 (1)
- Paediatric (1)
- Patient Controlled Analgesia (1)
- Patient Satisfaction (1)
- Pediatric (1)
- Pediatric malignancy (1)
- Phosphorylation (1)
- Physical fitness (1)
- Pneumococcal vaccination (1)
- Port (1)
- Preterm birth (1)
- Prevalence (1)
- Quality of life (1)
- Questionnaire (1)
- RNA isolation (1)
- RSV-A ON1 (1)
- RTPS1 (1)
- RTPS2 (1)
- Randomized controlled trial (1)
- Regulatory T cells (1)
- Regulatory T-cells (1)
- Remifentanil (1)
- Respiratory tract infection (1)
- Retinopathy (1)
- Rhabdomyosarcoma (1)
- Risk (1)
- Rituximab (1)
- Rotavirus (1)
- Röteln (1)
- SB332235 (1)
- SIRP-alpha (1)
- SMAD signaling (1)
- Safety (1)
- Schnitzler syndrome (1)
- Staphylococcus aureus (1)
- Surveillance (1)
- T and NK development (1)
- T cell plasticity (1)
- T lymphocytes (1)
- T-cell (1)
- T-cell responses (1)
- TB (1)
- TCR diversity (1)
- TH1-induced senescence (1)
- TH17 cells (1)
- TLR agonists (1)
- TMJ (1)
- TNAP (1)
- TREC (1)
- TRECs (1)
- T\(_H\)17 cells (1)
- Telomere (1)
- Telomeres (1)
- Th9 (1)
- Thrombosis (1)
- Tocilizumab (1)
- Toll-like receptor signaling (1)
- Treg (1)
- Trousseau's syndrome (1)
- United States (1)
- Universal mass vaccination (1)
- Ureaplasma (1)
- Ureaplasma species (1)
- VEGF (1)
- VIBE (1)
- VLBW (1)
- Vaccination (1)
- Vaccine (1)
- Varicella (1)
- Varizellen-Virus (1)
- Viruses (1)
- Vorschulkind (1)
- Wechsler intelligence scale (WISC-IV) (1)
- Wilm's tumor (1)
- achalasia (1)
- activity (1)
- acute (1)
- acute ITP (1)
- acute graft-versus-host disease (1)
- adenocarcinoma of the lung (1)
- adolescents (1)
- adrenal cancer (1)
- adrenal surgery (1)
- adrenalectomia (1)
- adrenocortical adenocarcinoma (1)
- adrenocortical carcinoma (1)
- adults (1)
- adverse pulmonary outcomes (1)
- aging (1)
- airway remodeling (1)
- alkaline phosphatase (1)
- allogeneic stem cell transplantation (1)
- alloreactive T cells (1)
- alveolar epithelium in vitro model, claudin-1, claudin-3, claudin-4, claudin-5 (1)
- amniotic infection (1)
- anaplastic medulloblastoma (1)
- antenatal inflammation (1)
- anti inflammation (1)
- anti-tumor agents (1)
- antibacterial activity (1)
- antibiotic resistance (1)
- antibiotic therapy (1)
- antibiotic use (1)
- antibody (1)
- antidepressants (1)
- antimicrobial activity (1)
- antimicrobial immunity (1)
- antimicrobial resistance (1)
- antimicrobial stewardship (1)
- antinuclear antibodies (1)
- anuria (1)
- anxiety disorders (1)
- apoptosis (1)
- arterial hypotension (1)
- arthrogryposis (1)
- asfotase alfa (1)
- asymmetry (1)
- atypical chemokine receptor 3 (1)
- atypical teratoid rhabdoid tumors (1)
- autoimmune encephalitis (1)
- autoinflammation (1)
- autologous stem cell transplantation (1)
- autophagy (1)
- axonopathy (1)
- barrier (1)
- beta-D-glucan (1)
- biomarker (1)
- bioreactor culture (1)
- bisphosphonate treatment (1)
- blastocysts (1)
- bleding disorders other than hemophilia (1)
- bleeding score (1)
- bone autoinflammation (1)
- bovine lactoferricin (1)
- brain development (1)
- brain tumor (1)
- breast cancer (1)
- breastfeeding (1)
- breath-hold (1)
- bronchopulmonary dysplasia (BPD) (1)
- bullae (1)
- caffein (1)
- caffeine (1)
- cancer microenvironment (1)
- cancer stem cells (1)
- cancer vaccines (1)
- cancer-targeted IL-12 (1)
- cardiogenic (1)
- cardiovascular risk (1)
- cell therapy (1)
- cellular signalling networks (1)
- central venous catheter (1)
- cerebral calcification (1)
- childhood leukemia (1)
- chorioamnionitis (1)
- chronic pulmonary insufficiency of prematurity (1)
- cidofovir (1)
- clinical application (1)
- clinical trial (1)
- cloning (1)
- coagulopathy (1)
- cognitive profile (1)
- combinatorial drug predictions (1)
- combined therapy (1)
- common variable immunodeficiency (1)
- complication (1)
- computer modelling (1)
- condyle pathomorphology (1)
- congenital dyserythropoietic anemia (1)
- connective tissue disorder (1)
- continuous positive airway pressure (CPAP) (1)
- corticosteroids (1)
- coverage (1)
- craniosynostosis (1)
- cytokine (1)
- cytoskeleton (1)
- cytotoxic effect (1)
- dendritic cells (1)
- depression (1)
- derivatives (1)
- desmoplastic small round cell tumor (1)
- diagnosis (1)
- diagnostic delay (1)
- diaphragmatic hypomotility (1)
- differentiation (1)
- diffusion-weighted MRI (1)
- disease severity (1)
- double negative B cells (1)
- drug therapy (1)
- dry lung syndrome (1)
- dual guidance (1)
- dysplasia (1)
- early onset sepsis (1)
- effector cells (1)
- endogenous pulmonary stem cells (1)
- endoglin (1)
- epidemiology (1)
- epitope mapping (1)
- essential tremor (1)
- exercise intervention (1)
- exercise testing (1)
- exercise tolerance (1)
- exposure (1)
- extracellular vesicles (1)
- extracorporeal membrane oxygenation (1)
- extracranial malignant rhabdoid tumor (1)
- factor XIII deficiency (1)
- fetal lung (1)
- fibrosis (1)
- follow up (1)
- forearm (1)
- fungal infection (1)
- gadoxetic acid (1)
- galactomannan (1)
- galectin-1 (1)
- galectin-3 (1)
- galectin-9 (1)
- gender gap (1)
- gene expression (1)
- general practitioner (1)
- genetics (1)
- genome-wide association study (1)
- genotype-phenotype correlation (1)
- germline mutation (1)
- glioblastoma multiforme (1)
- gliomedin (1)
- graft-versus host (1)
- group 3 (1)
- health (1)
- healthcare costs (1)
- healthy children (1)
- hematology (1)
- hemorrhagic (1)
- hemostasis and thrombosis (1)
- henoch-schönlein purpura (1)
- hospital exemption (1)
- hospitalization (1)
- human brain endothelium (1)
- human brain microvascular endothelial cells (1)
- human cerebral endothelial cells (1)
- human monocytes (1)
- humanized mice (1)
- humans (1)
- hyper-IgM syndrome type 2 (HIGM2) (1)
- hyperfibrinolysis (1)
- hyperoxia (1)
- hypertrophic osteodystrophy (1)
- hypogammaglobulinemia (1)
- imaging (1)
- immaturity (1)
- immune reconstitution (1)
- immune response (1)
- immunocytokine (1)
- immunodeficiency (1)
- immunoglobulin repertoire (1)
- immunoglobulins (1)
- immunology (1)
- immunomodulation (1)
- immunosenescence (1)
- immunotherapies (1)
- inattention/hyperactivity (1)
- infection spread (1)
- infections: pneumonia (1)
- infectious diseases management (1)
- inflammatory diseases (1)
- influenza A virus (1)
- influenza vaccination (1)
- inhibit (1)
- innate immune response (1)
- innate immunity training (1)
- intelligence (1)
- intensive care (1)
- interferon gamma (1)
- interleukin-8 (1)
- interleukin-9 (1)
- interventional radiology (1)
- intravenous immunoglobulins (1)
- invasiveness (1)
- ischemia/reperfusion injury (1)
- juvenile progressive respiratory insufficiency (1)
- ketogenic dietary therapy (KDT) (1)
- knowledge (1)
- lactoferricin B (1)
- late onset sepsis (1)
- lethality rate (1)
- lines (1)
- lipoblastoma (1)
- liquid biopsy (1)
- live-attenuated influenza vaccine (1)
- long-term outcome (1)
- loop region (1)
- luciferase (1)
- lung (1)
- lung injury (1)
- lung transplantation (1)
- lymph node dissection (1)
- lymphadenectomy (1)
- lymphocytes (1)
- lymphoplasmacellular osteomyelitis (1)
- maintenance therapy (1)
- malignant glioma (1)
- maternal critical care (1)
- measles (1)
- mechanisms (1)
- mesenchymal stromal cell (1)
- meta-analysis (1)
- metabolic reprogramming (1)
- metabolic syndrome (1)
- metabolism (1)
- metanalysis (1)
- metastasis-associated in colon cancer 1 (MACC1) (1)
- methylation (1)
- mhc molecules (1)
- mice (1)
- microbiome (1)
- middle cerebral artery occlusion (1)
- migration (1)
- mineralization (1)
- mitophagy (1)
- modular tumor tissue models (1)
- monocyte subsets (1)
- monocyte-derived DC (1)
- mouse models (1)
- movement disorder (1)
- movement disorders (1)
- multiple myeloma (1)
- multiple sclerosis (1)
- multiresistance (1)
- multi‑center cohort study (1)
- murine model (1)
- mutation (1)
- mutational targeting (1)
- myeloid (1)
- naive T cells (1)
- near infrared spectroscopy (1)
- neoepitope-derived peptides (1)
- neonatal immunology (1)
- neonatal meningitis (1)
- neonatal morbidity (1)
- neonatal outcome (1)
- neonatal renal failure (1)
- neuroblastoma (1)
- neuroblastoma – diagnosis (1)
- neurocognitive outcome (1)
- neutrophils (1)
- newly diagnosed ITP (1)
- non-invasive respiratory support (1)
- non-invasive ventilation (1)
- non-responder (1)
- nutrition education (1)
- observational (1)
- obstetrics (1)
- oligohydramnios sequence (1)
- orthotopic xenograft (1)
- osteomalacia (1)
- outcome (1)
- outpatient (1)
- p.R245H (1)
- p.S298P (1)
- paediatric cancer (1)
- pancreatic carcinoma (1)
- panic disorder (1)
- partially-supervised (1)
- participation in clinical trials (1)
- pediatric adrenocortical adenoma (1)
- pediatric adrenocortical carcinoma (1)
- pediatric immune thrombocytopenia (1)
- pediatric patients (1)
- pediatric stem cell transplantation (1)
- pediatrician (1)
- perioperative bleeding (1)
- peroral endoscopic myotomy (1)
- persistence (1)
- phosphorylation (1)
- platelet disorders (1)
- polymicrobial infection (1)
- polymorphism (1)
- population coverage (1)
- post-pandemic (1)
- potter sequence (1)
- prediction (1)
- pregnancy (1)
- prematurity (1)
- preschool children (1)
- preterm children (1)
- prevention program (1)
- primary antibody deficiency (1)
- primary care (1)
- primary immunodeficiencies (1)
- primary schoolchildren (1)
- probiotic prophylaxis (1)
- prognostic factors (1)
- prognostic marker (1)
- promoter (1)
- prophylaxis (1)
- prostaglandin E2 (1)
- protein expression (1)
- quality of life (1)
- quality-control (1)
- radiotherapy (1)
- randomised controlled trial (1)
- rare bone disease (1)
- rare diseases (1)
- rat (1)
- re-aim framework (1)
- real-time PCR (1)
- recommendations (1)
- refractory aGvHD (1)
- region (1)
- regional cerebral oxygenation saturation (1)
- regulatory dendritic cells (1)
- renal tubular dysgenesis (1)
- reoxygenation (1)
- resident memory T cells (1)
- resistant acid phosphatase (1)
- resolution (1)
- respiratory distress (1)
- respiratory distress syndrome (RDS) (1)
- respiratory-distress-syndrome (1)
- retroperitoneal tumor (1)
- review (1)
- rhabdomyosarcoma (1)
- rheumatoid arthritis (1)
- rickets (1)
- risk factors (1)
- safety (1)
- scoliosis (1)
- seasonal influenza (1)
- septic (1)
- serum (1)
- shock (1)
- shuttle run test (1)
- skin-to-skin contact (1)
- soft tissue sarcoma (1)
- soluble endoglin (1)
- somatic hypermutation (1)
- spectrum (1)
- speech motor impairment (1)
- spondylodysplastic Ehlers-Danlos syndrome (1)
- spondyloenchondrodysplasia (1)
- standard (1)
- stem/progenitor cells (1)
- steroid-resistant aGvHD (1)
- strength and difficulties (1)
- streptococci (1)
- stroke (1)
- suppression (1)
- suppressive function (1)
- surfactant (1)
- surfactant protein-A (1)
- surveillance (1)
- survey (1)
- sustained lung inflation (SLI) (1)
- sweat osmolality (1)
- sweat secretion rate (1)
- synovial fluid (1)
- synovitis (1)
- synthetic peptides (1)
- synthetic surfactant (1)
- systematic review (1)
- systemic lupus erythematosus (1)
- systemic sclerosis (1)
- teeth (1)
- telomere length (1)
- telomeres (1)
- therapeutic vaccines (1)
- therapy response (1)
- thermoregulation (1)
- thymectomy (1)
- thymus (1)
- tight junctions (1)
- tool (1)
- totally implantable venous access port (1)
- trained immunity (1)
- transcription factors (1)
- transmission (1)
- transmission model (1)
- trap (1)
- tremor (1)
- tumor-infiltrating lymphocytes (1)
- tumor-specific CD8+ T cells (1)
- tumors (1)
- tumour immunology (1)
- type I interferonopathy (1)
- vaccination program (1)
- vaccine (1)
- varicella (1)
- varicella-zoster virus immunosuppression (1)
- vascular access (1)
- vascular disturbances (1)
- vascular homeostasis (1)
- vasculitis (1)
- vasopressin (1)
- viral (1)
- volume (1)
- young children (1)
- zebrafish (1)
Institute
- Kinderklinik und Poliklinik (153) (remove)
Sonstige beteiligte Institutionen
- Department of Medicinal Chemistry, University of Vienna, Althanstraße 14, 1090 Vienna, Austria (1)
- Department of Paediatric Radiology, Institute of Diagnostic and Interventional Radiology, Josef-Schneider-Straße 2, Wuerzburg 97080, Germany (1)
- Department of Pediatrics, Pediatrics I, Innsbruck Medical University, Anichstr. 35, 6020, Innsbruck, Austria (1)
- Department of Pharmaceutical Technology and Biopharmaceutics, University of Vienna, Althanstraße 14, 1090 Vienna, Austria (1)
- Interdisciplinary Center for Clinical Research (IZKF), Würzburg, Germany (1)
- Interdisziplinäres Zentrum für Klinische Forschung (IZKF) (1)
EU-Project number / Contract (GA) number
- 229289 (1)
- 241778 (1)
- 609,020 (1)
- HEALTH-F2-2009-241778 (1)
Background: There is much evidence that T cells are strongly involved in the pathogenesis of localized and systemic forms of scleroderma (SSc). A dysbalance between FoxP3+ regulatory CD4+ T cells (Tregs) and inflammatory T-helper (Th) 17 cells has been suggested. Methods: The study aimed (1) to investigate the phenotypical and functional characteristics of Th17 and Tregs in SSc patients depending on disease manifestation (limited vs. diffuse cutaneous SSc, dcSSc) and activity, and (2) the transcriptional level and methylation status of Th17- and Treg-specific transcription factors. Results: There was a concurrent accumulation of circulating peripheral IL-17-producing CCR6+ Th cells and FoxP3+ Tregs in patients with dcSSc. At the transcriptional level, Th17- and Treg-associated transcription factors were elevated in SSc. A strong association with high circulating Th17 and Tregs was seen with early, active, and severe disease presentation. However, a diminished suppressive function on autologous lymphocytes was found in SSc-derived Tregs. Significant relative hypermethylation was seen at the gene level for RORC1 and RORC2 in SSc, particularly in patients with high inflammatory activity. Conclusions: Besides the high transcriptional activity of T cells, attributed to Treg or Th17 phenotype, in active SSc disease, Tregs may be insufficient to produce high amounts of IL-10 or to control proliferative activity of effector T cells in SSc. Our results suggest a high plasticity of Tregs strongly associated with the Th17 phenotype. Future directions may focus on enhancing Treg functions and stabilization of the Treg phenotype.
Introduction
Juvenile idiopathic arthritis is a heterogeneous T cell-mediated autoimmune disease with symptoms of premature aging of the immune system (immunosenescence). The present work is an investigation of immunosenescence parameters, such as quantity of naive and CD28- T cells, T cell receptor excision circles, relative telomere length and alterations of peripheral T cell replication, and was performed via comparison of a case of acute exacerbation of juvenile idiopathic arthritis against six patients with juvenile idiopathic arthritis with disease remission and six age-matched healthy donors over a follow-up course of 12 months.
Case presentation
Phenotypical T cell characterization and intracellular interferon γ, tumor necrosis factor α, and interleukin 2 production were studied in peripheral blood mononuclear cells from seven patients with juvenile idiopathic arthritis and six healthy control donors, with findings determined by flow cytometry. T cell receptor excision circles and relative telomere length quantification were performed on deoxyribonucleic acid isolated from naive (CD4+CD28+CD45RA+) T cells and investigated via reverse transcription polymerase chain reaction. Ki67 expression was studied by immunohistochemistry on naive T cells. The non-parametric Mann-Whitney U test and Wilcoxon test for two independent groups of variables were used to compare healthy donors with patients with juvenile idiopathic arthritis. During follow-up, patients with juvenile idiopathic arthritis showed lower total counts of naive and CD28-expressing T cells compared to healthy donors. Acute exacerbation led to low naive and CD28+ T cell populations and elevated proportions of Ki67-expressing CD4+ naive T cells. In conditions of exacerbation, T cell receptor excision circle numbers were in the lower range in patients with juvenile idiopathic arthritis and increased after follow-up. Healthy donors showed significantly higher relative telomere lengths compared to patients with juvenile idiopathic arthritis.
Conclusions
This investigation illustrates that the changes in T cell homeostasis in patients with juvenile idiopathic arthritis may be the result of several mechanisms, such as diminished thymus function and peripheral exertions to maintain the peripheral T cell pool. The results also demonstrate that hallmarks of immunosenescence such as decreased naive T cell levels and lower T cell receptor excision circle numbers can only be interpreted together with replication markers such as relative telomere length or Ki67 expression.
Background
Children with different underlying malignant diseases require long-term central venous access. As for port systems in a pectoral position, peripherally implanted port systems in the forearm revealed high levels of technical and clinical success in adult cohorts.
Objective
To investigate the technical and clinical outcomes of percutaneous central venous port implantation in the forearm in adolescents.
Materials and methods
Between April 2010 and August 2020, 32 children ages 9 to 17 years with underlying malignancy received 35 totally implantable venous access ports (TIVAPs) in the forearm. All venous port systems were peripherally inserted under ultrasound guidance. Correct catheter placement was controlled by fluoroscopy. As primary endpoints, the technical success, rate of complications and catheter maintenance were analyzed. Secondary endpoints were the side of implantation, vein of catheter access, laboratory results on the day of the procedure, procedural radiation exposure, amount of contrast agent and reasons for port device removal.
Results
Percutaneous TIVAP placement under sonographic guidance was technically successful in 34 of 35 procedures (97.1%). Procedure-related complications did not occur. During the follow-up, 13,684 catheter days were analyzed, revealing 11 complications (0.8 per 1,000 catheter-duration days), Of these 11 complications, 7 were major and 10 occurred late. In seven cases, the port device had to be removed; removal-related complications did not occur.
Conclusion
Peripheral TIVAP placement in the forearms of children is a feasible, effective and safe technique with good midterm outcome. As results are comparable with standard access routes, this technique may be offered as an alternative when intermittent venous access is required.
The aim of this research was to characterize cognitive abilities in patients with Glut1-Deficiency syndrome (Glut1DS) following ketogenic diet therapy (KDT). Methods: The cognitive profiles of eight children were assessed using the Wechsler Intelligence Scale (WISC-IV). The effect of ketogenic diet therapy (KDT) on individual subareas of intelligence was analyzed considering the potential influence of speech motor impairments. Results: Patients with Glut1DS showed a wide range of cognitive performance levels. Some participants showed statistically and clinically significant discrepancies between individual subdomains of intelligence. Both variables, KDT initiation as well as duration, had a positive effect on the overall IQ score. Significant correlations were partially found between the time of KDT initiation and the level of IQ scores, depending on the presence of expressive language test demands of the respective subtests of the WISC-IV. Accordingly, the participants benefited les in the linguistic cognitive domain. The discrepancies in cognitive performance profiles of patients with Glut1DS can be attributed to the possibility of a negative distortion of the results due to the influence of speech motor impairments. Conclusions: The individual access skills of test persons should be more strongly considered in test procedures for the assessment of intelligence to reduce the negative influence of motor deficits on test performance. Specific characterization and systematization of the speech disorder are indispensable for determining the severity of speech motor impairment in Glut1DS. Therefore, a stronger focus on dysarthria during diagnosis and therapy is necessary.
Preterm infants are susceptible to infection and their defense against pathogens relies largely on innate immunity. The role of the complement system for the immunological vulnerability of preterm infants is less understood. Anaphylatoxin C5a and its receptors C5aR1 and -2 are known to be involved in sepsis pathogenesis, with C5aR1 mainly exerting pro-inflammatory effects. Our explorative study aimed to determine age-dependent changes in the expression of C5aR1 and C5aR2 in neonatal immune cell subsets. Via flow cytometry, we analyzed the expression pattern of C5a receptors on immune cells isolated from peripheral blood of preterm infants (n = 32) compared to those of their mothers (n = 25). Term infants and healthy adults served as controls. Preterm infants had a higher intracellular expression of C5aR1 on neutrophils than control individuals. We also found a higher expression of C5aR1 on NK cells, particularly on the cytotoxic CD56\(^{dim}\) subset and the CD56\(^-\) subset. Immune phenotyping of other leukocyte subpopulations revealed no gestational-age-related differences for the expression of and C5aR2. Elevated expression of C5aR1 on neutrophils and NK cells in preterm infants may contribute to the phenomenon of “immunoparalysis” caused by complement activation or to sustained hyper-inflammatory states. Further functional analyses are needed to elucidate the underlying mechanisms.
(1) Background: Refractory acute graft-versus-host disease (R-aGvHD) remains a leading cause of death after allogeneic stem cell transplantation. Survival rates of 15% after four years are currently achieved; deaths are only in part due to aGvHD itself, but mostly due to adverse effects of R-aGvHD treatment with immunosuppressive agents as these predispose patients to opportunistic infections and loss of graft-versus-leukemia surveillance resulting in relapse. Mesenchymal stromal cells (MSC) from different tissues and those generated by various protocols have been proposed as a remedy for R-aGvHD but the enthusiasm raised by initial reports has not been ubiquitously reproduced. (2) Methods: We previously reported on a unique MSC product, which was generated from pooled bone marrow mononuclear cells of multiple third-party donors. The products showed dose-to-dose equipotency and greater immunosuppressive capacity than individually expanded MSCs from the same donors. This product, MSC-FFM, has entered clinical routine in Germany where it is licensed with a national hospital exemption authorization. We previously reported satisfying initial clinical outcomes, which we are now updating. The data were collected in our post-approval pharmacovigilance program, i.e., this is not a clinical study and the data is high-level and non-monitored. (3) Results: Follow-up for 92 recipients of MSC-FFM was reported, 88 with GvHD ≥°III, one-third only steroid-refractory and two-thirds therapy resistant (refractory to steroids plus ≥2 additional lines of treatment). A median of three doses of MSC-FFM was administered without apparent toxicity. Overall response rates were 82% and 81% at the first and last evaluation, respectively. At six months, the estimated overall survival was 64%, while the cumulative incidence of death from underlying disease was 3%. (4) Conclusions: MSC-FFM promises to be a safe and efficient treatment for severe R-aGvHD.
Acute graft-versus-host disease (aGvHD) is a severe and often life-threatening complication of allogeneic hematopoietic cell transplantation (allo-HCT). AGvHD is mediated by alloreactive donor T-cells targeting predominantly the gastrointestinal tract, liver, and skin. Recent work in mice and patients undergoing allo-HCT showed that alloreactive T-cells can be identified by the expression of α4β7 integrin on T-cells even before manifestation of an aGvHD. Here, we investigated whether the detection of a combination of the expression of T-cell surface markers on peripheral blood (PB) CD8\(^+\) T-cells would improve the ability to predict aGvHD. To this end, we employed two independent preclinical models of minor histocompatibility antigen mismatched allo-HCT following myeloablative conditioning. Expression profiles of integrins, selectins, chemokine receptors, and activation markers of PB donor T-cells were measured with multiparameter flow cytometry at multiple time points before the onset of clinical aGvHD symptoms. In both allo-HCT models, we demonstrated a significant upregulation of α4β7 integrin, CD162E, CD162P, and conversely, a downregulation of CD62L on donor T-cells, which could be correlated with the development of aGvHD. Other surface markers, such as CD25, CD69, and CC-chemokine receptors were not found to be predictive markers. Based on these preclinical data from mouse models, we propose a surface marker panel on peripheral blood T-cells after allo-HCT combining α4β7 integrin with CD62L, CD162E, and CD162P (cutaneous lymphocyte antigens, CLA, in humans) to identify patients at risk for developing aGvHD early after allo-HCT.
Background
Acute graft-versus-host disease (aGVHD) poses a major limitation for broader therapeutic application of allogeneic hematopoietic cell transplantation (allo-HCT). Early diagnosis of aGVHD remains difficult and is based on clinical symptoms and histopathological evaluation of tissue biopsies. Thus, current aGVHD diagnosis is limited to patients with established disease manifestation. Therefore, for improved disease prevention it is important to develop predictive assays to identify patients at risk of developing aGVHD. Here we address whether insights into the timing of the aGVHD initiation and effector phases could allow for the detection of migrating alloreactive T cells before clinical aGVHD onset to permit for efficient therapeutic intervention.
Methods
Murine major histocompatibility complex (MHC) mismatched and minor histocompatibility antigen (miHAg) mismatched allo-HCT models were employed to assess the spatiotemporal distribution of donor T cells with flow cytometry and in vivo bioluminescence imaging (BLI). Daily flow cytometry analysis of peripheral blood mononuclear cells allowed us to identify migrating alloreactive T cells based on homing receptor expression profiles.
Results
We identified a time period of 2 weeks of massive alloreactive donor T cell migration in the blood after miHAg mismatch allo-HCT before clinical aGVHD symptoms appeared. Alloreactive T cells upregulated α4β7 integrin and P-selectin ligand during this migration phase. Consequently, targeted preemptive treatment with rapamycin, starting at the earliest detection time of alloreactive donor T cells in the peripheral blood, prevented lethal aGVHD.
Conclusions
Based on this data we propose a critical time frame prior to the onset of aGVHD symptoms to identify alloreactive T cells in the peripheral blood for timely and effective therapeutic intervention.
Background: The European Centres of Reference Network for Cystic Fibrosis (ECORN-CF) established an Internet forum which provides the opportunity for CF patients and other interested people to ask experts questions about CF in their mother language. The objectives of this study were to: 1) develop a detailed quality assessment tool to analyze quality of expert answers, 2) evaluate the intra- and inter-rater agreement of this tool, and 3) explore changes in the quality of expert answers over the time frame of the project. Methods: The quality assessment tool was developed by an expert panel. Five experts within the ECORN-CF project used the quality assessment tool to analyze the quality of 108 expert answers published on ECORN-CF from six language zones. 25 expert answers were scored at two time points, one year apart. Quality of answers was also assessed at an early and later period of the project. Individual rater scores and group mean scores were analyzed for each expert answer. Results: A scoring system and training manual were developed analyzing two quality categories of answers: content and formal quality. For content quality, the grades based on group mean scores for all raters showed substantial agreement between two time points, however this was not the case for the grades based on individual rater scores. For formal quality the grades based on group mean scores showed only slight agreement between two time points and there was also poor agreement between time points for the individual grades. The inter-rater agreement for content quality was fair (mean kappa value 0.232 ± 0.036, p < 0.001) while only slight agreement was observed for the grades of the formal quality (mean kappa value 0.105 ± 0.024, p < 0.001). The quality of expert answers was rated high (four language zones) or satisfactory (two language zones) and did not change over time. Conclusions: The quality assessment tool described in this study was feasible and reliable when content quality was assessed by a group of raters. Within ECORN-CF, the tool will help ensure that CF patients all over Europe have equal possibility of access to high quality expert advice on their illness.
Background
Medulloblastoma is the most common malignant brain tumor in children and can be divided in different molecular subgroups. Patients whose tumor is classified as a Group 3 tumor have a dismal prognosis. However only very few tumor models are available for this subgroup.
Methods
We established a robust orthotopic xenograft model with a cell line derived from the malignant pleural effusions of a child suffering from a Group 3 medulloblastoma.
Results
Besides classical characteristics of this tumor subgroup, the cells display cancer stem cell characteristics including neurosphere formation, multilineage differentiation, CD133/CD15 expression, high ALDH-activity and high tumorigenicity in immunocompromised mice with xenografts exactly recapitulating the original tumor architecture.
Conclusions
This model using unmanipulated, human medulloblastoma cells will enable translational research, specifically focused on Group 3 medulloblastoma.